<DOC>
	<DOCNO>NCT01495208</DOCNO>
	<brief_summary>This open label study evaluate efficacy intravitreal aflibercept injection 2mg patient persistent FVPED despite least 6 consecutive injection ranibizumab 0.5 mg .</brief_summary>
	<brief_title>Open Label Study Evaluate Effect Alfilbercept Patients With ( FVPED ) Fibrovascular Pigment Epithelial Detachment</brief_title>
	<detailed_description>This open label study evaluate efficacy intravitreal aflibercept injection 2mg patient persistent FVPED despite least 6 consecutive injection ranibizumab 0.5 mg . Patients evaluate VRM New York neovascular AMD persistent sub-foveal FVPED OCT despite least 6 consecutive ranibizumab injection consider study . We aim recruit 25 patient study . There statistical test calculate sample size ; sample size 25 patient choose , make sure feasible financially conduct study logistically complete study within 24 week . This pilot study assess effect intravitreal aflibercept injection chronic , persistent FVPEDs ; currently data regard visual anatomical outcome group patient . Patients review baseline 4 week interval ( 28 ± 7 day ) . They receive intravitreal intravitreal aflibercept injection 2mg visit . The primary end point study 24 week baseline . Patients complete study receive 6 injection intravitreal aflibercept injection 2mg .</detailed_description>
	<mesh_term>Retinal Detachment</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Subfoveal FVPED assess use clinical examination OCT Best correct visual acuity study eye 20 85 letter ETDRS chart ( 20/30 20/800 Snellen equivalent ) Prior treatment least 6 consecutive injection ranibizumab 0.5 mg prior baseline visit ; last treatment ranibizumab exceed 45 day baseline visit . Pregnancy ( positive pregnancy test ) lactation Participation another simultaneous medical investigation trial Prior treatment ranibizumab therapy study eye within 30 day baseline Prior treatment PDT study eye Prior intravitreal injection corticosteroid ( triamcinolone , dexamethasone ) within 120 day baseline . Presence significant subfoveal fibrosis atrophy determine use SDOCT , fluorescein angiography clinical examination . Presence fibrous fibrocellular material occupy 50 % subRPE space ; assess use EDI OCT Presence RPE tear , determine clinical examination , FA , FAF OCT Intraocular surgery ( include cataract surgery ) study eye within 90 day precede baseline History par plana vitrectomy , submacular surgery surgical intervention vitreoretinal disease study eye Presence previous history diabetic macular edema proliferative diabetic retinopathy . History uveitis study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment , macular hole lamellar hole study eye Ocular periocular infection Active severe intraocular inflammation Uncontrolled glaucoma study eye ( defined IOP ≥ 30 mmHg despite treatment antiglaucoma medication ) In patient glaucoma , advanced field loss ; mean deviation threshold visual field 12 decibel . History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . History allergy fluorescein , ICG iodine , amenable treatment Known hypersensitivity aflibercept excipients</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>